Floatz logo

Rap-219

Focal Seizure

Rapport Therapeutics Inc.Phase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

24 Active assets in the Focal Seizure cohort.

Asset / SponsorPhaseRating
Eslicarbazepine Acetate
Sumitomo Pharma America, Inc.
Phase 4A
Pregabalin
Yung Shin Pharm. Ind. Co., Ltd.
Phase 4A
Lacosamide
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Phase 4A
Topamax
Mario Negri Institute for Pharmacological Research
Phase 4A
Oxcarbamezapine
Mario Negri Institute for Pharmacological Research
Phase 4A

View all 50 →

Same molecule, other indications

Rap-219 is also rated in:

epilepsyDormant
B
Indicative ·
59 / 100
View asset →
epilepsyDormant
CCC
Indicative ·
53 / 100
View asset →
bipolar I disorderDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →